The Multifaceted Role of CBD in Treating Addiction, Neurodegenerative, and Mental Health Disorders: Mechanisms, Risks, and Clinical Considerations

This podcast episode, hosted by Dr. Donnelly Snipes, provides an in-depth analysis of Cannabidiol (CBD) and its potential therapeutic applications in the treatment of substance use disorders, neurodegenerative conditions like Alzheimer's and Parkinson's, and various mental health issues including PTSD, anxiety, depression, and schizophrenia. The discussion centers on CBD's intricate interactions with the endocannabinoid system (ECS), modulating key neurotransmitters such as dopamine, serotonin, norepinephrine, and opioid receptors. A crucial distinction is made between CBD and THC, emphasizing CBD's non-rewarding nature and lack of psychogenic effects, making it a potentially safer option for individuals in recovery. The presentation details CBD's specific benefits, which include reducing the overall intake and motivation for alcohol and stimulants, blocking the rewarding effects of opioids like morphine and heroin, and mitigating drug and stress-induced conditioned place preference. Beyond addiction, CBD's antioxidant and anti-inflammatory properties are highlighted as beneficial in reducing liver damage associated with alcoholism and preventing neuronal loss. It also shows promise in reversing stimulant toxicity, improving cognitive deficits, and alleviating comorbid mental disorders. For PTSD, one study indicated a significant decrease in symptom severity, attributed to CBD's ability to modulate the hyperactive amygdala and serotonin system. A significant portion of the discussion is dedicated to critical distinctions, nuances, and practical advice. Dr. Snipes strongly emphasizes the necessity of physician supervision for anyone considering CBD, especially due to its extensive interactions with nearly all medications. A key warning is issued for drugs with a "grapefruit warning," as CBD inhibits the CYP2D6 enzyme responsible for their metabolism, potentially leading to toxic drug levels. The risk of serotonin syndrome, a potentially deadly condition, is highlighted when CBD is combined with antidepressants or opioids. Furthermore, the episode issues a severe contraindication for CBD use during pregnancy, citing its potential to inhibit embryo implantation, impair placenta development, and potentiate the harmful effects of alcohol, increasing the risk of Fetal Alcohol Spectrum Disorders. Finally, the podcast addresses the challenges posed by the largely unregulated CBD market. It underscores the significant variability in product potency and the absence of established therapeutic dosages, making self-medication inherently risky. Potential adverse effects at higher doses are outlined, including developmental toxicity, central nervous system inhibition, neurotoxicity, liver injuries, and reduced spermatogenesis. Despite these cautions, CBD is presented as a promising alternative or adjunctive treatment for a wide array of conditions, reinforcing the critical need for informed medical guidance, rigorous research into optimal dosages, and greater regulatory oversight to ensure patient safety and efficacy.

CBD oil or CBD interacts with just about every medication out there so we do want to make sure that they're aware of that and hopefully agree to if they're going to try to start taking CBD do it in a physician supervised capacity

The endocannabinoid system or ECS modulates dopamine that's really important to recognize

CBD is non rewarding it doesn't have the psychogenic properties of THC that is super important to remember especially for people who are in recovery because CBD is not going to get them high

treatment with CBD blocked the rewarding effects of morphine and heroin and prevented drug and stress induced reinstatement of condition place preference lasting up to two weeks post administration

CBD interestingly has the opposite effect of THC in the prefrontal cortex which is where we have our higher-order thinking and our impulse control and in the amygdala

in one study 91% of patients experienced a decrease in PTSD symptom severity as low as evidenced by lower scores on the pcl5 at 8 weeks post treatment as opposed to their initial baseline

all CBD mixtures are not created equal CBD is not regulated by the FDA with the exception there is one drug that is used to treat seizures in epilepsy that has been fda-approved but anything you get over-the-counter is not regulated by the FDA

prenatal cannabinoid exposure not just CBD but to any of the cannabinoids potentiates the harmful effects of alcohol increasing the risk of the development of fetal alcohol spectrum disorders and craniofacial malformations and eye defects